Sure Genomics Gets FDA Letter | GenomeWeb

This article has been updated to clarify details of FDA's letter.


NEW YORK (GenomeWeb) – The US Food and Drug Administration has sent a letter to Sure Genomics asking why the company is marketing its SureDNA sequencing test, which collects and analyzes saliva samples and reports disease risk and drug response information to patients, without its clearance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.